Published
Proton Pump Inhibitors in Treatment of Peptic Ulcers
Published in April 2013 Issue 2 (Vol. 3, Issue 2, 2013)

Abstract
Acid-related disorders, including gastro esophageal reflux disease (GERD), duodenal ulcers, and gastric ulcers, are managed by H2 receptor antagonists and proton pump inhibitors (PPIs). PPIs represent first choice for treating acid-peptic ulcers inhibits the gastric- H+/ K+ -ATPase through covalent binding to cysteine residues of the proton pump. Achlorhydria and acute renal failure are the most common drawbacks. A reversible acid pump antagonist (APAs), currently in clinical trial removes these problems. The APAs are the conceivable future drugs for the treatment of acid-peptic disorders.
Authors (4)
P.V. Gangurde
View all publications →J. S. Rajawat
View all publications →C.S. Chauhan
View all publications →R. K. Kamble
View all publications →Download Article
Best for printing and citation
File size: 0.0 MB
Format: PDF
Download Article
Best for printing and citation
File size: 0.0 MB
Format: PDF
Article Information
Published in:
April 2013 Issue 2 (Vol. 3, Issue 2, 2013)AJPTR32010
AJPTR-01-002183
2013-04-01
Article Impact
Views:5,759
Downloads:2,461
How to Cite
Gangurde & S., J. & Chauhan & K., R. (2013). Proton Pump Inhibitors in Treatment of Peptic Ulcers. American Journal of PharmTech Research, 3(2), xx-xx. https://ajptr.com/articles/AJPTR32010
Article Actions
More from this Issue
Insilicopharmacology: An overview
Ashok M. Khandekar, Sagar...Read more →
Novel Monoclonal Antibodies for Cancer Treatment: A Review
J. P. Lavande, P. B. Itek...Read more →
Muco/Bioadhesive Polymers in Buccal Drug Delivery- A Review
Bhavani Boddeda, Asim Bis...Read more →
More by These Authors
A Review on Gastro Retentive Drug Delivery Systems with the Special Focus on Floating Drug Delivery
2019 • Vol. 9, Issue 1
Read more →Compaction and Compressibility Characteristics of Modified Starches Derived from Plectranthus Esculentus by Direct Compression
2015 • Vol. 5, Issue 6
Read more →Design, Development and Characterization of Pyrazinamide Niosomal Dosage Form
2013 • Vol. 3, Issue 6
Read more →